Cagrilintide
Price range: $100.00 through $155.00
What is Cagrilintide?
Cagrilintide (NN9838/AM833) is a long-acting acylated analog of human amylin developed by Novo Nordisk. Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells that plays a role in post-prandial glucose regulation and satiety signaling. Cagrilintide was engineered with a C18 fatty diacid modification that enables albumin binding and extends its pharmacokinetic half-life, allowing for once-weekly subcutaneous dosing in clinical studies. The compound activates amylin receptors (AMY1 and AMY3), which are heterodimers of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Cagrilintide has been investigated in Phase 2 and Phase 3 clinical trials both as monotherapy and in combination with semaglutide (the CagriSema combination). It represents a novel approach to amylin receptor pharmacology with an extended duration of action.
Mechanism of Action
Cagrilintide has been investigated for its agonist activity at amylin receptors, particularly AMY1R and AMY3R. These receptors are heterodimeric complexes of the calcitonin receptor (CTR) with RAMP1 or RAMP3, respectively. Researchers observed that cagrilintide binding activates Gs-coupled cAMP signaling and downstream pathways in the area postrema and nucleus tractus solitarius, brain regions involved in satiety and food intake regulation. Studies suggest that amylin receptor activation slows gastric emptying, reduces glucagon secretion, and modulates appetite through central nervous system signaling. The C18 fatty diacid acylation allows non-covalent albumin binding in circulation, extending the half-life from minutes (native amylin) to approximately one week. In clinical studies, researchers observed that cagrilintide administration was associated with changes in body weight, appetite scores, and glycemic parameters. The compound’s selectivity profile across calcitonin family receptors has been characterized in receptor binding studies.
Published Research
Phase 2 Clinical Trial
Lau et al. (2021) investigated cagrilintide in a randomized, dose-ranging Phase 2 trial in subjects with overweight or obesity. Researchers observed dose-dependent changes in body weight over 26 weeks compared to placebo, establishing the compound’s clinical activity profile [1].
CagriSema Combination
Enebo et al. (2021) investigated the combination of cagrilintide with semaglutide in a Phase 1b study. Researchers observed that the combination was associated with greater changes in body weight than either compound alone, suggesting complementary mechanisms of amylin and GLP-1 receptor agonism [2].
Amylin Receptor Pharmacology
Hay et al. (2015) reviewed the pharmacology of amylin receptors, describing the receptor heterodimer structures, signaling pathways, and physiological functions that provide the foundation for cagrilintide’s mechanism of action [3].
Product Specifications
| Product | Cagrilintide Lyophilized Powder |
|---|---|
| Available Sizes | 5mg, 10mg |
| Purity | ≥99% (HPLC verified) |
| CAS Number | 2375393-84-7 |
| Sequence | Acylated amylin analog (modified human amylin sequence with C18 fatty diacid) |
| Molecular Formula | C₁₇₅H₂₇₂N₅₀O₅₅S₃ |
| Molecular Weight | 4,026.56 g/mol |
| Appearance | White lyophilized powder in glass vial |
| Storage | Store lyophilized at -20°C. Reconstituted solution at 2-8°C, use within 14 days. |
| Testing | Third-party tested — Certificate of Analysis available |
Frequently Asked Questions
Cagrilintide is a long-acting acylated analog of human amylin developed by Novo Nordisk. It activates amylin receptors and has been investigated in clinical trials for metabolic research.
The CAS registry number for Cagrilintide is 2375393-84-7.
Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. It is involved in post-prandial glucose regulation and satiety signaling.
Cagrilintide is modified with a C18 fatty diacid that enables albumin binding, extending its half-life from minutes to approximately one week.
Store lyophilized Cagrilintide at -20°C. Once reconstituted, store at 2-8°C and use within 14 days.
CagriSema is a combination of cagrilintide and semaglutide being investigated for complementary amylin and GLP-1 receptor agonism in clinical trials by Novo Nordisk.
References
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID: 34798060
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. Lancet. 2021;397(10286):1736-1748. PMID: 33894838
- Hay DL, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600. PMID: 26071095
Customer Reviews
Fast shipping, well-packaged. Product quality is top-notch.
Nice quality. Website could use more research documentation.
Consistent quality across multiple orders. Very satisfied.
Outstanding quality. This is my go-to source now.
Really happy with this. Clean, pure, well-packaged.
